The Australia & New Zealand research antibodies market size was valued at USD 98.4 million in 2018 and is anticipated to grow at a CAGR of 8.4% during the forecast period. A rise in the number of initiatives being undertaken by the Australian government to advance the biotechnology sector is expected to fuel the growth in the country. In May 2019, Federal Labor offered businesses an R&D tax offset for collaborating with science-based agencies and universities, such as The Commonwealth Scientific and Industrial Research Organisation (CSIRO), to promote innovation and knowledge in the biotechnology sector. In addition, a 10% tax can be added to the calculated tax offset if a business is collaborating with any public institution. This plan would help in increasing R&D investments in Australia to 3% of GDP by 2030 and is expected to act as a key tool for fostering an alliance between research and industry, thereby improving industrial capabilities in Australia. R&D tax incentive in Australia has encouraged biotechnology companies in the region to conduct R&D.
For instance, in 2018, Shape Pharmaceuticals, Inc. supported R&D investments in the Australian biotechnology industry by conducting clinical trials to study the effect of SHP-141 on patients diagnosed with psoriasis. These tax incentives help companies achieve a cost advantage while selecting clinical trial sites for R&D processes.
A rise in R&D investments by the government is also expected to boost the market. In 2018, the Victorian government allocated USD 1.5 million for the establishment of an Advanced Biotechnology Manufacturing Platform to enhance the production of antibodies, vaccines, stem cells, and growth factors, among others, for testing in human clinical trials. This facility would enable various Australian biotechnology companies to conduct R&D in the state, thereby generating jobs and propelling the growth of various companies currently conducting clinical trials in Victoria. The government is also promoting the development of the biotechnology sector through Future Industries Fund.
Growth in stem cell and neurobiology-based research is expected to boost the market over the forecast period. The Center of Research Excellence in Neuromuscular Disorders Australia is a wide collaboration of neuromuscular experts, who use advanced technologies and approaches in science & medicine to improve diagnosis. In addition, it aims to transform treatment into effective therapy of neurological diseases from compassionate management. The Australian Neuromuscular Network was formed in the year 2010 by the Center of Research Excellence in Neuromuscular Disorders along with other neuromuscular specialists, scientists, and professionals across New Zealand and Australia.
A rise in the prevalence of neurological disorders is expected to boost the market. According to the Neurological Foundation of New Zealand, by 2051, about one-third of the population in New Zealand will be 65 years and above. The prevalence of dementia is therefore expected to increase, leading to a rise in R&D pertaining to treatment for various neurological disorders. However, stringent government regulations that can limit research activities are expected to restrain the market growth.
On the basis of product, Australia & New Zealand research antibodies market is segmented into primary and secondary antibodies. Primary antibodies held the largest share and are anticipated to witness the highest CAGR owing to the rise in the adoption of reagents developed using antibodies, due to the various benefits associated with them such as greater specificity, easy availability, and suitability in various research applications.
Similarly, primary antibodies are anticipated to grow at a faster rate during the forecast period due to varied applications in research. In addition, the rise in the prevalence of chronic diseases, such as diabetes, cancer, and Alzheimer’s disease, is leading to an increase in the adoption of primary antibodies. Increasing R&D in the country is further anticipated to boost the adoption of secondary antibodies as well. Thus, the rising adoption of these antibodies in research for the development of alternative therapies is anticipated to create significant demand for these products over the forecast period.
Pharmaceutical & biotechnology companies held the largest share of the end-use segment in 2018, which can be attributed to increase in the adoption of antibodies in drug development and research organizations. Contract research organizations are anticipated to grow at a lucrative CAGR during the forecast period owing to cost-effectiveness.
The academic & research institutes segment is expected to witness constant growth owing to the presence of various academic research groups that are involved in the study of complex biological systems using advanced reagents. Benefits such as a greater understanding of biological processes and complex systems are anticipated to create growth opportunities in the segment.
Contract research organizations are anticipated to grow at a lucrative CAGR during the forecast period. The majority of the companies prefer CROs owing to the various advantages associated with contract services. These benefits include cost advantage, increased efficiency of services, and enhanced productivity, which help a company focus on its core expertise.
On the basis of antibody type, the market is segmented into monoclonal and polyclonal antibodies. Monoclonal antibodies held the largest market share due to an increase in research on genomics and personalized medicine, which has led to an increase in the use of these antibodies. As monoclonal antibodies are relatively cost-effective, they are anticipated to grow at a higher rate than polyclonal antibodies.
Polyclonal antibodies have several advantages over monoclonal in various diagnostic settings. Polyclonal antibodies are often the most preferred option in routine laboratory tests such as Enzyme-Linked Immunosorbent Assay (ELISA), microarray assays, western blotting, flow cytometry, and immunohistochemistry.
Their production does not require skilled professionals, and large batches can be produced as per client requirements. These antibodies can recognize multiple antigens on one epitope and can, therefore, be utilized in the study of various diseases ranging from cancer to metabolic
Polyclonal antibodies are relatively inexpensive in comparison with monoclonal antibodies, which may fuel their demand in low-budget and non-funded research projects. However, polyclonal antibodies can differ from batch to batch depending on the manufacturing and quality control process. These antibodies can recognize multiple epitopes, thus increasing the probability of nonspecific antigen binding.
On the basis of technology, the Australia & New Zealand research antibodies market is segmented into western blotting, immunoprecipitation, immunochemistry, ELISA, immunofluorescence, flow cytometry, and other technologies. Western blotting held the largest share of the technology segment in 2018 owing to rising demand for rapid diagnostic methods. On the other hand, technical upgradation is anticipated to create growth prospects for technologies in the pipeline. ELISA is anticipated to witness the highest CAGR during the forecast period owing to the conventional use of polyclonal antibodies in sandwich ELISA.
ELISA is an analytical test that essentially uses antibodies to identify substances in samples. These tests are most often used to accurately diagnose diseases, such as AIDS, Lyme disease, syphilis, pernicious anemia, Rocky Mountain spotted fever, squamous cell carcinoma, chickenpox, shingles, and other bacterial & viral infections.
Western blotting held the largest share in 2018 owing to the rise in the prevalence of diseases with a limited number of treatment options. Western blotting offers high accuracy and sensitivity and is considered a gold standard for testing. In addition, an increase in government initiatives to fund research activities is one of the factors contributing to the highest market share held by this segment, as it is conventionally used in research laboratories.
The mouse segment held the largest share in 2018 as mice are convenient to use during the production of antibodies for research purposes and have a wide range of applications. Other segment is expected to grow exponentially, as it has a wide range of applications.
The use of murine monoclonal antibodies is increasing in various end-use settings, which is expected to positively impact market growth. Mice have been predominantly used in the production of antibodies. The structural similarities in mice and human antibodies are a prime factor responsible for high adoption. Cost-effectiveness and the ability to multiply quickly are among the factors fueling the growth of this segment.
Moreover, mouse-derived monoclonal and polyclonal antibodies are relatively easier to produce and possess greater specificity. Technological advancements in the development processes of these products, such as hybridoma technology that aids in the production of monoclonal antibodies in specialized cells are further augmenting the demand for mouse antibodies.
Rabbits are also extensively used for the production of antibodies, owing to various advantages such as higher affinity and specificity in comparison with antisera obtained from other animal hosts. The higher specificity of these products makes them ideal for use in the detection of small molecules, such as pollutants; toxins; hormones; drugs; nonprotein targets, such as carbohydrates & lipids; and post-translational alterations such as phosphorylation.
Oncology held the largest share of the application segment in 2018. The largest share can be attributed to the growing prevalence of cancer, which leads to an increase in the need for R&D pertaining to advanced therapeutics. On the other hand, stem cell is anticipated to witness lucrative CAGR during the forecast period owing to a significant increase in stem cell research.
The rising prevalence of infectious diseases, the growing geriatric population, decreasing immunity levels, and rising awareness among people about communicable diseases are some of the high-impact-rendering drivers of the market. The growing incidence of autoimmune diseases coupled with the limited presence of advanced therapeutics is predominantly driving the segment growth. Significant advancements in immunology research have boosted the adoption of research antibodies in recent years.
Oncology accounted for the largest share of research antibodies in 2018. The segment is also anticipated to grow at a considerable CAGR owing to an increased incidence of cancer. According to WHO, the number of new cancer cases is anticipated to increase by approximately 70.0% in the next two decades. Monoclonal antibodies are also used for the diagnosis of lymphoid & myeloid malignancies, tissue typing, and immunological intervention using a passive antibody.
Owing to the steady increase in the demand for transplantable tissues and low-quality donor cells, the stem cell research segment is expected to grow. Moreover, increasing adoption of cell isolation and culture, which involves the use of research antibodies, is further anticipated to broaden segment growth prospects.
Some major players in this market are PerkinElmer, Inc.; F.Hoffmann La Roche Ltd.; Thermo Fisher Scientific; Merck Millipore; Bio-Rad Laboratories; Abcam PLC; BD; Lonza Group; Cell Signaling Technology, Inc.; and Agilent Technologies.
An increase in the number of products launched by market players is expected to fuel market growth. For instance, in April 2019, Bio-Rad launched a range of isotype-specific secondary antibodies-IgG1, IgG2a, and IgG2b. These products are used to offer specificity when used in ELISA, imaging, western blotting, and flow cytometry, among others, as well as for improved signaling.
Mergers & acquisitions and collaborations are some of the other strategic initiatives undertaken by leading players to gain market share, for instance, Abcam Plc acquired Calico Biolabs. This initiative helped the company expand its product portfolio through the addition of high-quality recombinant rabbit monoclonal antibodies for immunohistochemistry. As per the agreement, Abcam was to also expand its custom rabbit monoclonal antibody production. These factors are further anticipated to aid growth during the forecast period.
Base year for estimation
Actual estimates/Historical data
2015 - 2017
2019 - 2026
Revenue in USD Million & CAGR from 2019 to 2026
Revenue forecast, company share, competitive landscape, growth factors, and trends
Australia, New Zealand
15% free customization scope (equivalent to 5 analyst working days)
If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization
This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2015 to 2026. For the purpose of this study, Grand View Research has segmented the Australia & New Zealand research antibodies market report on the basis of product, type, technology, source application, end-use, and country:
Product Outlook (Revenue, USD Million, 2015 - 2026)
Type Outlook (Revenue, USD Million, 2015 - 2026)
Technology Outlook (Revenue, USD Million, 2015 - 2026)
Source Outlook (Revenue, USD Million, 2015 - 2026)
Application Outlook (Revenue, USD Million, 2015 - 2026)
End-use Outlook (Revenue, USD Million, 2015 - 2026)
Academic & Research Institutes
Contract Research Organizations
Pharmaceutical & Biotechnology Companies
Regional Outlook (Revenue, USD Million, 2015 - 2026)
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
ESOMAR & Great Work to Place Certified
ISO 9001:2015 & 27001:2022 Certified
"The quality of research they have done for us has been excellent."
Biopharmaceutical innovators are at the forefront of the human response to the coronavirus pandemic. A significant number of major biotech firms are in the midst of a race to investigate the Sars-Cov-2 genome and prepare a viable vaccine for the same. As compared to the speed of response to SARS/MERs etc, the biotech entities are investigating SARs-Cov-2 at an unprecedented rate and a considerable amount of funds are being put into the R&D. With multiple candidates in trial, the public and private sectors are anticipated to work in unison for the foreseeable period, until a vaccine is developed for Covid-19. The report will account for Covid19 as a key market contributor.